194 related articles for article (PubMed ID: 33197837)
41. Atypical ductal hyperplasia: breast DCE-MRI can be used to reduce unnecessary open surgical excision.
Bertani V; Urbani M; La Grassa M; Balestreri L; Berger N; Frauenfelder T; Boss A; Marcon M
Eur Radiol; 2020 Jul; 30(7):4069-4081. PubMed ID: 32144463
[TBL] [Abstract][Full Text] [Related]
42. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
43. Breast intraductal papillomas without atypia in radiologic-pathologic concordant core-needle biopsies: Rate of upgrade to carcinoma at excision.
Pareja F; Corben AD; Brennan SB; Murray MP; Bowser ZL; Jakate K; Sebastiano C; Morrow M; Morris EA; Brogi E
Cancer; 2016 Sep; 122(18):2819-27. PubMed ID: 27315013
[TBL] [Abstract][Full Text] [Related]
44. High-risk lesions diagnosed at MRI-guided vacuum-assisted breast biopsy: imaging characteristics, outcome of surgical excision or imaging follow-up.
Okamoto S; Chen ST; Covelli JD; DeMartini WB; Daniel BL; Ikeda DM
Breast Cancer; 2020 May; 27(3):405-414. PubMed ID: 31838725
[TBL] [Abstract][Full Text] [Related]
45. Benign breast papillomas without atypia diagnosed with core needle biopsy: Outcome of surgical excision and imaging follow-up.
Polat DS; Knippa EE; Ganti R; Seiler SJ; Goudreau SH
Eur J Radiol; 2020 Oct; 131():109237. PubMed ID: 32905954
[TBL] [Abstract][Full Text] [Related]
46. Not All Ductal Carcinomas In Situ Are Created IDLE (Indolent Lesions of Epithelial Origin).
Alexander M; Beyda J; Nayak A; Jaffer S
Arch Pathol Lab Med; 2019 Jan; 143(1):99-104. PubMed ID: 29932858
[TBL] [Abstract][Full Text] [Related]
47. Ipsilateral and Concurrent Breast Cancer and Atypical Ductal Hyperplasia: Does Atypia Also Need Surgical Excision?
Amin AL; Fan F; Winblad OD; Larson KE; Wagner JL
Ann Surg Oncol; 2020 Nov; 27(12):4786-4794. PubMed ID: 32705514
[TBL] [Abstract][Full Text] [Related]
48. Ductal carcinoma in situ: Is core needle biopsy ever enough?
Caswell-Smith P; Wall M
J Med Imaging Radiat Oncol; 2017 Feb; 61(1):29-33. PubMed ID: 27554420
[TBL] [Abstract][Full Text] [Related]
49. Flat ductal intraepithelial neoplasia 1A diagnosed at stereotactic core needle biopsy: is excisional biopsy indicated?
Becker AK; Gordon PB; Harrison DA; Hassell PR; Hayes MM; van Niekerk D; Wilson CM
AJR Am J Roentgenol; 2013 Mar; 200(3):682-8. PubMed ID: 23436863
[TBL] [Abstract][Full Text] [Related]
50. Reporting the greatest linear extent of ductal carcinoma in situ on needle core biopsy.
Reisenbichler ES; Hameed O
Hum Pathol; 2016 Apr; 50():140-5. PubMed ID: 26997448
[TBL] [Abstract][Full Text] [Related]
51. Surgical upgrade rate of breast atypia to malignancy: An academic center's experience and validation of a predictive model.
Linsk A; Mehta TS; Dialani V; Brook A; Chadashvili T; Houlihan MJ; Sharma R
Breast J; 2018 Mar; 24(2):115-119. PubMed ID: 28833923
[TBL] [Abstract][Full Text] [Related]
52. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
53. Benign Breast Intraductal Papillomas Without Atypia at Core Needle Biopsies: Is Surgical Excision Necessary?
Moseley T; Desai B; Whitman GJ; Robinson EK; Saunders T; Gonzalez A; He H
Ann Surg Oncol; 2021 Mar; 28(3):1347-1355. PubMed ID: 32860176
[TBL] [Abstract][Full Text] [Related]
54. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ.
Huo L; Sneige N; Hunt KK; Albarracin CT; Lopez A; Resetkova E
Cancer; 2006 Oct; 107(8):1760-8. PubMed ID: 16977650
[TBL] [Abstract][Full Text] [Related]
55. Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia.
Peña A; Shah SS; Fazzio RT; Hoskin TL; Brahmbhatt RD; Hieken TJ; Jakub JW; Boughey JC; Visscher DW; Degnim AC
Breast Cancer Res Treat; 2017 Jul; 164(2):295-304. PubMed ID: 28474262
[TBL] [Abstract][Full Text] [Related]
56. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
57. Management of papillary breast lesions diagnosed on core-needle biopsy: clinical pathologic and radiologic analysis of 276 cases with surgical follow-up.
Rizzo M; Linebarger J; Lowe MC; Pan L; Gabram SG; Vasquez L; Cohen MA; Mosunjac M
J Am Coll Surg; 2012 Mar; 214(3):280-7. PubMed ID: 22244207
[TBL] [Abstract][Full Text] [Related]
58. Role of vacuum assisted excision in minimising overtreatment of ductal atypias.
McMahon MA; Haigh I; Chen Y; Millican-Slater RA; Sharma N
Eur J Radiol; 2020 Oct; 131():109258. PubMed ID: 32919262
[TBL] [Abstract][Full Text] [Related]
59. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
60. Predictive value of ductal carcinoma in situ with invasive breast cancer in core needle biopsies for final pathologic size of intraductal elements.
Matsumoto H; Ishii A; Nakada N; Koki A; Unesoko M; Abe N; Zaha H
Virchows Arch; 2022 Apr; 480(4):739-748. PubMed ID: 34993592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
